Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04166071 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Opioids and Social Support Enhanced Extinction Effects

Study acronym: SSO
StatusEnrolling by Invitation
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 2026 → Dec 1, 2026
See other at-risk trials from University of California, Los Angeles

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Primary and study completion pushed from Sep 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 11 words
  2. Notable Primary and study completion dates: Sep 2025 to Sep 2026v11
  3. Minor Primary and study completion dates: Jul 2025 to Sep 2025v10
  4. Notable Primary and study completion dates: Dec 2024 to Jul 2025v9
  5. Notable Primary and study completion dates: Dec 2023 to Dec 2024v8
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Primary and study completion dates: Mar 2023 to Dec 2023
    • Trial status: Recruiting to Enrolling by Invitation
    • Site details revised at 2 of 2 sites
    v7
  2. Notable Primary and study completion dates: Mar 2022 to Mar 2023v6
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Nov 2021 to Dec 13, 2021
    v5
  4. Notable Start date: Jan 2021 to Nov 2021v4
  5. Notable Start date: Jul 2020 to Jan 2021
    • Primary and study completion dates: Dec 2021 to Mar 2022
    v3
  6. Notable Primary and study completion dates: Sep 2020 to Dec 2021
    • Start date: Nov 2019 to Jul 2020
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of California, Los Angeles researchers will recruit healthy participants (age 18-35) to participate in a study examining whether the administration of naltrexone, an opioid antagonist, eliminates the ability of social support figure reminders to enhance fear extinction--a process during which a threatening cue is learned to not predict a negative or threatening outcome (i.e., electric shock) by being repeatedly presented in the absence of that outcome. After undergoing an email screening, a telephone screening, an in lab screening, and a health screening, 60 participants will be enrolled in the study. During the experiment, 30 participants will be administered naltrexone and 30 participants will be administered placebo (both participants and experimenters will be blind to condition) before undergoing a fear extinction procedure in which threatening cues--cues that predict electric shock--will be paired with either an image of a social support figure (provided by participants) or a second threatening cue. These pairings will be presented repeatedly in the absence of shock in order for fear extinction to occur. Participants will return for a follow-up test to determine if fear extinction was successful.
Trial Details
NCT Number NCT04166071
Lead Sponsor University of California, Los Angeles
Collaborators: National Institute of Mental Health (NIMH)
Conditions
(from sponsor)
Fear
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov